We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+37.69%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$7.48B
AUM Growth
+$1.44B
Cap. Flow
-$77.6M
Cap. Flow %
-1.04%
Top 10 Hldgs %
23.83%
Holding
336
New
58
Increased
161
Reduced
69
Closed
35
Avg Time Held
6.6 quarters
Top 10 Avg Time Held
4.2 quarters
Top 20 Avg Time Held
4.6 quarters

Top Buys

Rank Stock Value
1
AVLN icon
Avalyn Pharma
AVLN
+$39.7M
2
CDNS icon
Cadence Design Systems
CDNS
+$29.6M
3
RELY icon
Remitly
RELY
+$27.3M
4
DELL icon
Dell
DELL
+$25.5M
5
FITB icon
Fifth Third Bancorp
FITB
+$25.3M

Top Sells

Rank Stock Value
1
XMTR icon
Xometry
XMTR
+$57.8M
2
PLD icon
Prologis
PLD
+$56.1M
3
GH icon
Guardant Health
GH
+$44M
4
AXSM icon
Axsome Therapeutics
AXSM
+$44M
5
GLBE icon
Global E Online
GLBE
+$37.6M

Sector Composition

Rank Sector Weight
1 Healthcare 36.37%
2 Technology 22.57%
3 Industrials 20.48%
4 Energy 5.51%
5 Utilities 4.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AIT icon
51
Applied Industrial Technologies
AIT
$12.2B
$48.6M 0.65%
143,966
+22,679
+19% +$6.96M
2024 Q1
9 quarters
MBX icon
52
MBX Biosciences
MBX
$2.39B
$48.2M 0.64%
873,492
-16,508
-2% -$577K
2025 Q4
2 quarters
CYTK icon
53
Cytokinetics
CYTK
$8.64B
$48.1M 0.64%
564,398
+85,300
+18% +$6.12M
2022 Q4
14 quarters
IONS icon
54
Ionis Pharmaceuticals
IONS
$7.06B
$45.6M 0.61%
575,000
– –
2025 Q4
2 quarters
AVLN icon
55
Avalyn Pharma
AVLN
$1.03B
$45.3M 0.61%
+1,375,486
New +$39.7M
2026 Q2
0 quarters
RVMD icon
56
Revolution Medicines
RVMD
$40.6B
$42.7M 0.57%
227,845
-33,580
-13% -$4.9M
2023 Q2
12 quarters
STE icon
57
Steris
STE
$21.2B
$42.1M 0.56%
199,560
+4,925
+3% +$1.06M
2020 Q2
24 quarters
BE icon
58
Bloom Energy
BE
$77B
$41.7M 0.56%
138,192
+432
+0.3% +$111K
2025 Q4
2 quarters
FERG icon
59
Ferguson
FERG
$43B
$41.2M 0.55%
173,453
+3,993
+2% +$963K
2023 Q3
11 quarters
IMMX icon
60
Immix Biopharma
IMMX
$728M
$40.1M 0.54%
3,891,019
+1,342,000
+53% +$12.4M
2025 Q4
2 quarters
CDNS icon
61
Cadence Design Systems
CDNS
$93.3B
$39.1M 0.52%
104,219
+84,368
+425% +$29.6M
2024 Q3
7 quarters
LOW icon
62
Lowe's Companies
LOW
$105B
$39M 0.52%
176,976
+6,341
+4% +$1.44M
2013 Q4
50 quarters
AXON icon
63
Axon Enterprise
AXON
$33.7B
$38.9M 0.52%
69,514
-329
-0.5% -$138K
2025 Q1
5 quarters
MDB icon
64
MongoDB
MDB
$30.4B
$38.6M 0.52%
114,962
+52,588
+84% +$15.8M
2025 Q2
4 quarters
CLDX icon
65
Celldex Therapeutics
CLDX
$2.2B
$38.6M 0.52%
1,037,000
– –
2020 Q2
24 quarters
FAST icon
66
Fastenal
FAST
$58.4B
$38.5M 0.52%
804,046
+6,461
+0.8% +$293K
2024 Q4
6 quarters
FTDR icon
67
Frontdoor
FTDR
$5.33B
$37.7M 0.5%
486,594
+362
+0.1% +$23.2K
2025 Q2
4 quarters
TLN icon
68
Talen Energy Corp
TLN
$18.1B
$37.5M 0.5%
97,373
-19,810
-17% -$7.26M
2025 Q2
4 quarters
KMTS icon
69
Kestra Medical Technologies
KMTS
$1.6B
$36.8M 0.49%
1,446,742
+878
+0.1% +$18.4K
2025 Q1
5 quarters
TMDX icon
70
Transmedics
TMDX
$2.78B
$36.5M 0.49%
548,874
+50
+0% +$4.23K
2023 Q2
12 quarters
PVLA icon
71
Palvella Therapeutics
PVLA
$1.86B
$35.4M 0.47%
231,484
-1,764
-0.8% -$214K
2025 Q4
2 quarters
APGE icon
72
DELISTED
Apogee Therapeutics
APGE
$34.5M 0.46%
260,000
-297,423
-53% -$26.8M
2025 Q4
2 quarters
FIX icon
73
Comfort Systems
FIX
$56B
$34.4M 0.46%
17,370
+8,563
+97% +$15.5M
2025 Q4
2 quarters
DXCM icon
74
DexCom
DXCM
$32.4B
$33.6M 0.45%
498,202
+3,199
+0.6% +$213K
2025 Q4
2 quarters
DFTX icon
75
Definium Therapeutics
DFTX
$4.64B
$33.4M 0.45%
710,000
+23,838
+3% +$589K
2026 Q1
1 quarter
1 2
3
4 5

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Eventide Asset Management held 336 positions worth $7.48B, up 24% from $6.05B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management's Q2 2026 filing shows 58 new, 161 increased, 69 reduced and 35 closed positions. Its largest new stake was Avalyn Pharma: 1,375,486 shares worth $45.3M. The largest sale was Xometry, an estimated $57.8M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q2 2026 buy was Avalyn Pharma: 1,375,486 shares worth $45.3M.
  • Eventide Asset Management added most to Cadence Design Systems in Q2 2026, an estimated $29.6M increase.
  • Eventide Asset Management's biggest Q2 2026 reduction was Xometry, cutting an estimated $57.8M.
  • Eventide Asset Management fully exited Prologis in Q2 2026, selling an estimated $56.1M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $7.48B portfolio in Q2 2026.
  • Eventide Asset Management opened 58 new positions and closed 35 in Q2 2026.
  • Eventide Asset Management's portfolio value rose 24% quarter-over-quarter to $7.48B.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.